Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
48.38
-4.22 (-8.02%)
Jul 30, 2026, 3:40 PM HKT
Biocytogen Pharmaceuticals (Beijing) Employees
Biocytogen Pharmaceuticals (Beijing) had 1,443 employees as of December 31, 2025. The number of employees increased by 326 or 29.19% compared to the previous year.
Employees
1,443
Change (1Y)
326
Growth (1Y)
29.19%
Revenue / Employee
1.23M HKD
Profits / Employee
228.81K HKD
Market Cap
49.57B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,443 | 326 | 29.19% |
| Dec 31, 2024 | 1,117 | 51 | 4.78% |
| Dec 31, 2023 | 1,066 | -282 | -20.92% |
| Dec 31, 2022 | 1,348 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 21,435 |
| Innovent Biologics | 7,502 |
| Genscript Biotech | 6,165 |
| 3SBio | 6,109 |
| Shanghai Henlius Biotech | 3,762 |
| Akeso | 3,761 |
| RemeGen | 3,048 |
| Shanghai Junshi Biosciences | 2,903 |
Biocytogen Pharmaceuticals (Beijing) News
- 14 days ago - Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals - South China Morning Post
- 4 weeks ago - Court Clears Biocytogen's RenNano® in Landmark Patent Dispute Against Harbour - Business Upturn
- 6 months ago - Strengthening Translational Research in India: GVSAP and Biocytogen Expand Collaboration - Business Upturn
- 11 months ago - Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions - Financial Post
- 1 year ago - Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Business Upturn
- 1 year ago - Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development - Financial Post
- 1 year ago - Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing - Financial Post
- 1 year ago - Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform - Business Upturn